ArticleBritish journal of cancer2021

A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.

Geoffrey I Shapiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.